These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31193101)

  • 1. Threshold for Pre-existing Antibody Levels Limiting Transduction Efficiency of Systemic rAAV9 Gene Delivery: Relevance for Translation.
    Meadows AS; Pineda RJ; Goodchild L; Bobo TA; Fu H
    Mol Ther Methods Clin Dev; 2019 Jun; 13():453-462. PubMed ID: 31193101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgG-cleavage protein allows therapeutic AAV gene delivery in passively immunized MPS IIIA mice.
    Bobo TA; Samowitz PN; Robinson MI; Montes LI; Forsberg LJ; Feng R; Nicely NI; Fu H
    Gene Ther; 2023 Apr; 30(3-4):377-385. PubMed ID: 36253453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates.
    Murrey DA; Naughton BJ; Duncan FJ; Meadows AS; Ware TA; Campbell KJ; Bremer WG; Walker CM; Goodchild L; Bolon B; La Perle K; Flanigan KM; McBride KL; McCarty DM; Fu H
    Hum Gene Ther Clin Dev; 2014 Jun; 25(2):72-84. PubMed ID: 24720466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy.
    Fu H; Meadows AS; Pineda RJ; Kunkler KL; Truxal KV; McBride KL; Flanigan KM; McCarty DM
    Hum Gene Ther Clin Dev; 2017 Dec; 28(4):187-196. PubMed ID: 29064732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB.
    Meadows AS; Duncan FJ; Camboni M; Waligura K; Montgomery C; Zaraspe K; Naughton BJ; Bremer WG; Shilling C; Walker CM; Bolon B; Flanigan KM; McBride KL; McCarty DM; Fu H
    Hum Gene Ther Clin Dev; 2015 Dec; 26(4):228-42. PubMed ID: 26684447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.
    Fu H; Meadows AS; Ware T; Mohney RP; McCarty DM
    Mol Ther; 2017 Mar; 25(3):792-802. PubMed ID: 28143737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.
    Hinderer C; Katz N; Buza EL; Dyer C; Goode T; Bell P; Richman LK; Wilson JM
    Hum Gene Ther; 2018 Mar; 29(3):285-298. PubMed ID: 29378426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.
    Fitzpatrick Z; Leborgne C; Barbon E; Masat E; Ronzitti G; van Wittenberghe L; Vignaud A; Collaud F; Charles S; Simon Sola M; Jouen F; Boyer O; Mingozzi F
    Mol Ther Methods Clin Dev; 2018 Jun; 9():119-129. PubMed ID: 29766022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting.
    Velazquez VM; Meadows AS; Pineda RJ; Camboni M; McCarty DM; Fu H
    Mol Ther Methods Clin Dev; 2017 Mar; 4():159-168. PubMed ID: 28345001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9.
    Okada H; Ishibashi H; Hayashita-Kinoh H; Chiyo T; Nitahara-Kasahara Y; Baba Y; Watanabe S; Takeda S; Okada T
    Mol Ther Nucleic Acids; 2013 May; 2(5):e95. PubMed ID: 23715217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy.
    Long BR; Sandza K; Holcomb J; Crockett L; Hayes GM; Arens J; Fonck C; Tsuruda LS; Schweighardt B; O'Neill CA; Zoog S; Vettermann C
    Mol Ther Methods Clin Dev; 2019 Jun; 13():440-452. PubMed ID: 31193016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
    Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
    Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle.
    Ghosh A; Yue Y; Duan D
    J Gene Med; 2006 Mar; 8(3):298-305. PubMed ID: 16385549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficient and durable gene delivery of self complementary adeno-associated virus 6 vector and impact of pre-existing immunity].
    Tu L; Sun L; Xue J; Zhang Y; Lu Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Dec; 29(6):1150-5. PubMed ID: 23469547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
    Janelidze S; Nordström U; Kügler S; Brundin P
    J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Capsid Proteins Impact Transduction Efficiency of Haploid Adeno-Associated Virus Vectors.
    Chai Z; Zhang X; Dobbins AL; Frost EA; Samulski RJ; Li C
    Viruses; 2019 Dec; 11(12):. PubMed ID: 31835440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors.
    Hirsch ML; Wolf SJ; Samulski RJ
    Methods Mol Biol; 2016; 1382():21-39. PubMed ID: 26611576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction.
    Nakai H; Thomas CE; Storm TA; Fuess S; Powell S; Wright JF; Kay MA
    J Virol; 2002 Nov; 76(22):11343-9. PubMed ID: 12388694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs.
    Majowicz A; Nijmeijer B; Lampen MH; Spronck L; de Haan M; Petry H; van Deventer SJ; Meyer C; Tangelder M; Ferreira V
    Mol Ther Methods Clin Dev; 2019 Sep; 14():27-36. PubMed ID: 31276009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.